Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML
Samuel John, Heyu Chen, Mi Deng, et al.
Molecular Therapy (2018) Vol. 26, Iss. 10, pp. 2487-2495
Open Access | Times Cited: 107

Showing 1-25 of 107 citing articles:

Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng, Wen Jiang, Betty Y.S. Kim, et al.
Nature reviews. Cancer (2019) Vol. 19, Iss. 10, pp. 568-586
Open Access | Times Cited: 744
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Xiaomin Zhang, Lingling Zhu, Hui Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 204
Emerging agents and regimens for AML
Hongtao Liu
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 183
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
Hao Wang, Gurbakhash Kaur, Alexander Sankin, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 154
FTO in cancer: functions, molecular mechanisms, and therapeutic implications
Yangchan Li, Rui Su, Xiaolan Deng, et al.
Trends in cancer (2022) Vol. 8, Iss. 7, pp. 598-614
Open Access | Times Cited: 134
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
Faroogh Marofi, Heshu Sulaiman Rahman, Zaid Al-Obaidi, et al.
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 113
High expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour‐associated T lymphocyte infiltration
Huafu Li, Qiao Su, Bo Li, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 8, pp. 4452-4465
Open Access | Times Cited: 99
New strategies to treat AML: novel insights into AML survival pathways and combination therapies
Ramya Nair, Alejandro Salinas-Illarena, Hanna‐Mari Baldauf
Leukemia (2020) Vol. 35, Iss. 2, pp. 299-311
Closed Access | Times Cited: 71
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
Rebecca M. Richards, Feifei Zhao, Katherine A. Freitas, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 6, pp. 648-665
Open Access | Times Cited: 64
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance
Ian Ferguson, Bonell Patiño-Escobar, Sami T. Tuomivaara, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 62
New insights into the role of the Nrf2 signaling pathway in green tea catechin applications
Marjan Talebi, Mohsen Talebi, Tahereh Farkhondeh, et al.
Phytotherapy Research (2021) Vol. 35, Iss. 6, pp. 3078-3112
Closed Access | Times Cited: 59
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Chunrun Qu, Hao Zhang, Hui Cao, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 45
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy
Tatjana Sauerer, Giuliano Filippini Velázquez, Christoph Schmid
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 34
Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix
Dallas B. Flies, Solomon Langermann, Christina Jensen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 31
Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L
Christopher J. Lafargue, Paola Amero, Kyunghee Noh, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia
Cecilia Restelli, Marco Ruella, Luca Paruzzo, et al.
Blood Cancer Discovery (2024) Vol. 5, Iss. 4, pp. 234-248
Closed Access | Times Cited: 9
Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
Xun Gui, Mi Deng, Hao Song, et al.
Cancer Immunology Research (2019) Vol. 7, Iss. 8, pp. 1244-1257
Open Access | Times Cited: 67
LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells
Zunling Li, Mi Deng, Fangfang Huang, et al.
Cellular and Molecular Immunology (2019) Vol. 17, Iss. 3, pp. 272-282
Open Access | Times Cited: 56
Detection of Immune Checkpoint Receptors – A Current Challenge in Clinical Flow Cytometry
Benjamin Shibru, Katharina Fey, Stephan Fricke, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 43
LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis
Guojin Wu, Yixiang Xu, Robbie D. Schultz, et al.
Nature Cancer (2021) Vol. 2, Iss. 11, pp. 1170-1184
Open Access | Times Cited: 42
Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
Jennifer Marvin‐Peek, Bipin N. Savani, Olalekan O. Oluwole, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 497-497
Open Access | Times Cited: 30
Biomarkers as targets for CAR-T/NK cell therapy in AML
Ruonan Shao, Zijian Li, Hong-Lei Xin, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 21
Human leukocyte immunoglobulin-like receptors in health and disease
Silvia Redondo-García, Christopher Barritt, Charys Papagregoriou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells
Heyu Chen, Yuanzhi Chen, Mi Deng, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000515-e000515
Open Access | Times Cited: 45
LILRB4-targeting Antibody–Drug Conjugates for the Treatment of Acute Myeloid Leukemia
Yasuaki Anami, Mi Deng, Xun Gui, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 11, pp. 2330-2339
Open Access | Times Cited: 43
Page 1 - Next Page

Scroll to top